Bristol-Myers Squibb to acquire Mirati in a $4.8 billion deal

Bristol-Myers Squibb is set to acquire cancer drugmaker Mirati Therapeutics for $58 per share in cash, representing a $4.8 billion equity value.

Bristol-Myers Squibb will finance the transaction with a combination of cash and debt.

The transaction is expected to be dilutive to Bristol-Myers Squibb’s non-GAAP earnings per share by approximately 35 cents per share in the first 12 months after the transaction closes.

Mirati stockholders will receive one non-tradeable Contingent Value Right for each Mirati share held, potentially worth $12.00 per share in cash.

The U.S. health regulator had in December approved Mirati’s lung cancer drug, Krazati, to treat adults with advanced lung cancer.


News7g: Update the world's latest breaking news online of the day, breaking news, politics, society today, international mainstream news .Updated news 24/7: Entertainment, the World everyday world. Hot news, images, video clips that are updated quickly and reliably

Related Articles

Back to top button